Advanced

The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer.

Canesin, Giacomo LU ; Evans Axelsson, Susan LU ; Hellsten, Rebecka LU ; Sterner, Olov; Krzyzanowska, Agnieszka LU ; Andersson, Tommy LU and Bjartell, Anders LU (2015) In European Urology
Abstract
Signal transducer and activator of transcription 3 (STAT3) is known to be involved in the progression of prostate cancer (PCa) and is a key factor in drug resistance and tumor immunoescape. As a result, it represents a promising target for PCa therapy. We studied the effects of the STAT3 inhibitor galiellalactone (GL) on tumor growth and metastatic spread in vitro and in vivo. The effect of GL on cell viability, apoptosis, and invasion was studied in vitro using androgen-independent DU145 and DU145-Luc cell lines. For in vivo studies, mice were injected orthotopically with DU145-Luc cells and treated with daily intraperitoneal injections of GL for 6 wk. GL significantly reduced the growth of the primary tumor and the metastatic spread of... (More)
Signal transducer and activator of transcription 3 (STAT3) is known to be involved in the progression of prostate cancer (PCa) and is a key factor in drug resistance and tumor immunoescape. As a result, it represents a promising target for PCa therapy. We studied the effects of the STAT3 inhibitor galiellalactone (GL) on tumor growth and metastatic spread in vitro and in vivo. The effect of GL on cell viability, apoptosis, and invasion was studied in vitro using androgen-independent DU145 and DU145-Luc cell lines. For in vivo studies, mice were injected orthotopically with DU145-Luc cells and treated with daily intraperitoneal injections of GL for 6 wk. GL significantly reduced the growth of the primary tumor and the metastatic spread of PCa cells to regional and distal lymph nodes in vivo. Treatment with GL also resulted in decreased cell proliferation and increased apoptosis compared with controls. In vitro, GL reduces the viability and invasive abilities of DU145-Luc cells and induces apoptosis. Our results showed that tumor growth and early metastatic dissemination of PCa can be significantly reduced by GL, indicating its potential use as a therapeutic compound in advanced metastatic PCa. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
European Urology
publisher
Elsevier
external identifiers
  • pmid:26144873
  • scopus:84934300279
  • wos:000370356100019
ISSN
1873-7560
DOI
10.1016/j.eururo.2015.06.016
language
English
LU publication?
yes
id
bc74187f-b03b-41c3-b3ed-c8e55bdcf17b (old id 7750680)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26144873?dopt=Abstract
date added to LUP
2015-08-06 22:22:46
date last changed
2017-04-30 16:14:51
@article{bc74187f-b03b-41c3-b3ed-c8e55bdcf17b,
  abstract     = {Signal transducer and activator of transcription 3 (STAT3) is known to be involved in the progression of prostate cancer (PCa) and is a key factor in drug resistance and tumor immunoescape. As a result, it represents a promising target for PCa therapy. We studied the effects of the STAT3 inhibitor galiellalactone (GL) on tumor growth and metastatic spread in vitro and in vivo. The effect of GL on cell viability, apoptosis, and invasion was studied in vitro using androgen-independent DU145 and DU145-Luc cell lines. For in vivo studies, mice were injected orthotopically with DU145-Luc cells and treated with daily intraperitoneal injections of GL for 6 wk. GL significantly reduced the growth of the primary tumor and the metastatic spread of PCa cells to regional and distal lymph nodes in vivo. Treatment with GL also resulted in decreased cell proliferation and increased apoptosis compared with controls. In vitro, GL reduces the viability and invasive abilities of DU145-Luc cells and induces apoptosis. Our results showed that tumor growth and early metastatic dissemination of PCa can be significantly reduced by GL, indicating its potential use as a therapeutic compound in advanced metastatic PCa.},
  author       = {Canesin, Giacomo and Evans Axelsson, Susan and Hellsten, Rebecka and Sterner, Olov and Krzyzanowska, Agnieszka and Andersson, Tommy and Bjartell, Anders},
  issn         = {1873-7560},
  language     = {eng},
  month        = {07},
  publisher    = {Elsevier},
  series       = {European Urology},
  title        = {The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer.},
  url          = {http://dx.doi.org/10.1016/j.eururo.2015.06.016},
  year         = {2015},
}